Press Release Details

View all news

Arcus Biosciences Announces Participation at Two Investor Conferences in September

August 22, 2018

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the Company will be participating in the following upcoming investor conferences:

  • Citi's 13th Annual Biotech Conference in Boston on Wednesday, September 5, 2018. At 3:15 pm ET, Terry Rosen, Ph.D., Chief Executive Officer, will participate in a panel discussion entitled, "Targeted Therapies Oncology – Aiming for the Bull’s Eye."
  • Morgan Stanley 16th Annual Global Healthcare Conference in New York City on Thursday, September 13, 2018. At 4:40 pm ET, Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat. Individuals may access the live audio webcast of the fireside chat by visiting the “Events & Presentations” section of the Company’s website at https://investors.arcusbio.com/investors/events-and-presentations. A replay of the webcast will be available for 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Arcus Biosciences
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com
or
Nicole Arndt, 510-284-4728
narndt@arcusbio.com

Source: Arcus Biosciences

Categories: Press Releases
View all news